Translational Reliability Is Not a Claim. It Is a System.
In preclinical drug development, failure rarely stems from a lack of innovation. More often, it is driven by unreliable translation-models that look promising in vivo but fail to predict human outcomes.
translational reliability
At Prisys Biotechnologies, we define translational reliability not as a slogan, but as a system: precision delivery, objective readouts, regulatory-grade execution, and global reproducibility.
In 2025, this system delivered measurable outcomes:
- 82%+ annual revenue growth
- 75%+ contribution from global sponsors
- 150+ contracts executed
- 100% sponsor audit pass rate
More importantly, it reshaped how global R&D teams evaluate risk in Non-Human Primate (NHP) studies.
CNS programs fail not because targets are wrong, but because delivery and exposure are uncontrolled.
In 2025, Prisys fully operationalized its MRI-Guided CNS Delivery Platform, integrating real-time imaging with convection-enhanced delivery (CED) workflows. This platform enables:
- Sub-millimeter targeting accuracy for gene and cell therapies in deep brain structures
- Real-time monitoring of infusion dynamics, minimizing reflux and off-target exposure
- Clinically aligned procedures, executed in a preclinical NHP setting
MRI-guided delivery provides visual confirmation of where the therapeutic actually goes. For sponsors advancing CNS assets toward IND or first-in-human studies, this distinction directly translates into regulatory confidence and decision-making clarity.
AI-Driven Behavioral Analytics: From Observation to Quantification
Traditional behavioral assessments rely heavily on observer scoring-introducing variability, bias, and limited resolution.
In 2025, Prisys scaled its AI-based NHP Behavior Analysis System (BehaviorAtlas®) across CNS and neurology programs. Using markerless multi-view 3D capture and deep learning algorithms, we now quantify:
- Parkinsonian tremor patterns
- Gait instability and fine motor deficits
- Cognitive task performance and longitudinal behavioral drift
This approach delivers:
- Objective, observer-independent efficacy endpoints
- High-density behavioral datasets, enabling smaller cohort designs
- Improved sensitivity for early pharmacodynamic signals
For sponsors balancing cost, animal welfare, and statistical power, AI-driven analytics are no longer optional-they are foundational.
In 2025, over 75% of Prisys' project volume originated from global sponsors, including multinational pharma and emerging biotech companies.
This shift reflects more than geographic reach. It reflects trust in:
- AAALAC-accredited operations
- Audit-ready documentation and SOP execution
- Consistency across long-horizon, data-dense studies
Operating from Shanghai while adhering to global compliance standards allows Prisys to combine operational efficiency with regulatory rigor-serving as an extension of sponsor R&D teams in Boston, Basel, or Tokyo.
Our 100% sponsor audit pass rate is not an endpoint; it is evidence that translational reliability can be systematized.
Looking Ahead: Scaling What Works
As we enter 2026, Prisys now offers:
- 40+ translational-ready NHP models
- Coverage across CNS, immunology, metabolic, and systemic diseases
- Fully integrated in vivo, imaging, and analytics workflows
If your program demands not just data-but data you can trust to make irreversible decisions-we welcome the conversation.
